DE69526428D1 - Verfahren zur erhöhung der bioverfügbarkeit oraler arzneimittel - Google Patents

Verfahren zur erhöhung der bioverfügbarkeit oraler arzneimittel

Info

Publication number
DE69526428D1
DE69526428D1 DE69526428T DE69526428T DE69526428D1 DE 69526428 D1 DE69526428 D1 DE 69526428D1 DE 69526428 T DE69526428 T DE 69526428T DE 69526428 T DE69526428 T DE 69526428T DE 69526428 D1 DE69526428 D1 DE 69526428D1
Authority
DE
Germany
Prior art keywords
bioavailability
compound
bioenhancer
increasing
medicinal products
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69526428T
Other languages
English (en)
Other versions
DE69526428T2 (de
Inventor
Leslie Benet
Yuan Wu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of California
Original Assignee
University of California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of California filed Critical University of California
Application granted granted Critical
Publication of DE69526428D1 publication Critical patent/DE69526428D1/de
Publication of DE69526428T2 publication Critical patent/DE69526428T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/26—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving oxidoreductase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/49—Cinchonan derivatives, e.g. quinine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)
DE69526428T 1994-02-02 1995-01-11 Verfahren zur erhöhung der bioverfügbarkeit oraler arzneimittel Expired - Fee Related DE69526428T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/190,288 US5567592A (en) 1994-02-02 1994-02-02 Screening method for the identification of bioenhancers through the inhibition of P-glycoprotein transport in the gut of a mammal
PCT/US1995/000347 WO1995020980A1 (en) 1994-02-02 1995-01-11 Method for increasing bioavailability of oral pharmaceutical compositions

Publications (2)

Publication Number Publication Date
DE69526428D1 true DE69526428D1 (de) 2002-05-23
DE69526428T2 DE69526428T2 (de) 2002-10-10

Family

ID=22700726

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69526428T Expired - Fee Related DE69526428T2 (de) 1994-02-02 1995-01-11 Verfahren zur erhöhung der bioverfügbarkeit oraler arzneimittel

Country Status (10)

Country Link
US (3) US5567592A (de)
EP (2) EP1127579A3 (de)
JP (2) JPH09508623A (de)
AT (1) ATE216260T1 (de)
AU (1) AU1562995A (de)
CA (1) CA2177175A1 (de)
DE (1) DE69526428T2 (de)
DK (1) DK0742722T3 (de)
ES (1) ES2174928T3 (de)
WO (1) WO1995020980A1 (de)

Families Citing this family (116)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2140929C (en) 1992-08-25 2006-09-12 Michael L. Vazquez Hydroxyethylamino sulfonamides useful as retroviral protease inhibitors
US7141609B2 (en) 1992-08-25 2006-11-28 G.D. Searle & Co. α- and β-amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors
US5567592A (en) * 1994-02-02 1996-10-22 Regents Of The University Of California Screening method for the identification of bioenhancers through the inhibition of P-glycoprotein transport in the gut of a mammal
US6395770B1 (en) 1995-10-26 2002-05-28 Baker Norton Pharmaceuticals, Inc. Method and compositions for administering taxanes orally to human patients
US6964946B1 (en) 1995-10-26 2005-11-15 Baker Norton Pharmaceuticals, Inc. Oral pharmaceutical compositions containing taxanes and methods of treatment employing the same
US6245805B1 (en) * 1995-10-26 2001-06-12 Baker Norton Pharmaceuticals, Inc. Method, compositions and kits for increasing the oral bioavailability of pharmaceutical agents
US5968972A (en) * 1995-10-26 1999-10-19 Baker Norton Pharmaceuticals, Inc. Method for increasing the oral bioactivity of pharmaceutical agents
US5820915A (en) * 1996-06-27 1998-10-13 Bioavailability Systems, L.L.C. Method for the preparation of a first-pass effective citrus-derived substance and product thereof
US6124477A (en) * 1996-06-27 2000-09-26 Bioavailability Systems, Llc Anti-first-pass effect compounds
US6057367A (en) 1996-08-30 2000-05-02 Duke University Manipulating nitrosative stress to kill pathologic microbes, pathologic helminths and pathologically proliferating cells or to upregulate nitrosative stress defenses
IE960761A1 (en) * 1996-10-31 1998-05-06 Univ Dublin City Combinations for use in increasing the potency of a¹substrate for multidrug resistance related protein
US6008222A (en) * 1996-12-04 1999-12-28 Bristol-Myers Squibb Company Method for oral administration of buspirone and nefazodone
PL337064A1 (en) * 1997-05-27 2000-07-31 Baker Norton Pharma Method of and compositions for orally administering taxanes to human beings
AU725965C (en) * 1997-08-14 2004-04-22 Aventisub Llc Method of enhancing bioavailability of fexofenadine and its derivatives
US6451815B1 (en) 1997-08-14 2002-09-17 Aventis Pharmaceuticals Inc. Method of enhancing bioavailability of fexofenadine and its derivatives
BR9812131A (pt) 1997-08-19 2000-07-18 Warner Lambert Co Composições contendo bergamotina para aumentar a biodisponibilidade oral de agentes farmacêuticos
US6063809A (en) * 1997-08-26 2000-05-16 Bioavailability Systems, Llc Anti-first-pass effect compounds
US5962522A (en) * 1997-09-05 1999-10-05 Avmax, Inc. Propyl gallate to increase bioavailability of orally administered pharmaceutical compounds
US6180666B1 (en) 1997-09-05 2001-01-30 Anmax, Inc. Use of gallic acid esters to increase bioavailability of orally administered pharmaceutical compounds
AU9785698A (en) * 1997-10-02 1999-04-27 Microcide Pharmaceuticals, Inc. Fungal efflux pump inhibitors
US6040188A (en) * 1997-11-18 2000-03-21 The Regents Of The University Of California In vitro gastrointestinal mimetic protocol for measuring bioavailable contaminants
US6312662B1 (en) * 1998-03-06 2001-11-06 Metabasis Therapeutics, Inc. Prodrugs phosphorus-containing compounds
ATE327735T1 (de) * 1998-04-01 2006-06-15 Jagotec Ag Taxan-mikroemulsionen
US6410041B1 (en) 1998-04-28 2002-06-25 Trustees Of Tufts College Culturing cells in presence of amphipathic weak bases and/or cations and multiple drug resistance inhibitor containing reserpine
US6995022B1 (en) 1998-05-26 2006-02-07 Board Of Trustees Of The University Of Illinois Screening of xenobiotics and endogenous compounds for metabolic transformation, formation of toxic metabolites, and bioavailability
US6706691B1 (en) 1998-07-15 2004-03-16 Board Of Regents, The University Of Texas System Immunosupportive drug sparing diet
EP1133281A1 (de) * 1998-11-20 2001-09-19 RTP Pharma Inc. Dispergierbare mit phospholipid stabilisierte mikropartikel
US7205404B1 (en) 1999-03-05 2007-04-17 Metabasis Therapeutics, Inc. Phosphorus-containing prodrugs
US6803387B1 (en) 1999-03-19 2004-10-12 Abbott Gmbh & Co. Kg Treatment of neuropathic pain or fibromyalgia
US7311924B2 (en) * 1999-04-01 2007-12-25 Hana Biosciences, Inc. Compositions and methods for treating cancer
US7244450B2 (en) * 1999-04-01 2007-07-17 Inex Pharmaceuticals Corporation Compositions and methods for treating lymphoma
US6723338B1 (en) * 1999-04-01 2004-04-20 Inex Pharmaceuticals Corporation Compositions and methods for treating lymphoma
EP1242058A1 (de) * 1999-04-07 2002-09-25 Pfizer Products Inc. Verwendung von cyp2d6 hemmer in kombinierten therapie
AU4955200A (en) * 1999-05-17 2000-12-05 Cancer Research Ventures Limited A method of improving bioavailability of orally administered drugs, a method of screening for enhancers of such bioavailability and novel pharmaceutical compositions for oral delivery of drugs
US6426342B2 (en) 1999-08-16 2002-07-30 Revaax Pharmaceuticals, Llc Use of β-lactamase inhibitors as neuroprotectants
WO2001012184A1 (en) 1999-08-16 2001-02-22 Revaax Pharmaceuticals, Llc Neurotherapeutic composition and method
US6489319B2 (en) 1999-08-16 2002-12-03 Revaax Pharmaceuticals, Llc Neurotherapeutic use of carboxypeptidase inhibitors
AU7361400A (en) 1999-09-08 2001-04-10 Metabasis Therapeutics, Inc. Prodrugs for liver specific drug delivery
US7732404B2 (en) 1999-12-30 2010-06-08 Dexcel Ltd Pro-nanodispersion for the delivery of cyclosporin
EP1118333A1 (de) * 2000-01-18 2001-07-25 Eurand International S.P.A. Zusammensetzungen mit erhöhter oraler Bioverfügbarkeit
US6750246B1 (en) 2000-02-03 2004-06-15 Bristol-Myers Squibb Company C-4 carbonate taxanes
US20020142950A1 (en) * 2000-02-11 2002-10-03 Hayward Neil J. Methods for enhancing the bioavailability of a drug
IL141438A0 (en) * 2000-02-23 2002-03-10 Pfizer Prod Inc Method of increasing the bioavailability and tissue penetration of azithromycin
US6784178B2 (en) 2000-04-12 2004-08-31 Cornell Research Foundation, Inc. Pharmacotherapy for vascular dysfunction associated with deficient nitric oxide bioactivity
EP1365806A2 (de) * 2000-04-19 2003-12-03 Johns Hopkins University Verwendung von no aktivatoren zur vermeidung und behandlung von gastrointestinalen krankheiten
US6830897B2 (en) * 2000-04-26 2004-12-14 Pfizer Inc. High throughput screen for reducing drug candidate attrition
US20040029100A1 (en) * 2000-09-11 2004-02-12 Sharom Frances J. Rapid screen to identify p-glycoprotein substrates and high affinity modulators
EP1333811A4 (de) * 2000-10-16 2004-03-03 Neopharm Inc Liposomale mitoxantron-formulierung
US7115565B2 (en) 2001-01-18 2006-10-03 Pharmacia & Upjohn Company Chemotherapeutic microemulsion compositions of paclitaxel with improved oral bioavailability
US6579898B2 (en) 2001-03-01 2003-06-17 Pfizer Inc. Compositions having improved bioavailability
US20030082228A1 (en) * 2001-05-09 2003-05-01 Inex Pharmaceuticals Corporation Anti-angiogenic therapy using liposome-encapsulated chemotherapeutic agents
GB0113663D0 (en) * 2001-06-05 2001-07-25 Novartis Ag Use of organic compounds
GB0114532D0 (en) * 2001-06-14 2001-08-08 Jagotec Ag Novel compositions
GB0119480D0 (en) * 2001-08-09 2001-10-03 Jagotec Ag Novel compositions
PL206018B1 (pl) * 2001-10-19 2010-06-30 Isotechnika Inc Preparat farmaceutyczny, sposób jego wytwarzania, mikroemulsja i zastosowanie tego preparatu farmaceutycznego
CZ2004500A3 (cs) * 2001-10-23 2005-03-16 Ono Pharmaceutical Co., Ltd. Léčivo osahující kombinaci triazaspiro[5.5] undekanového derivátu s inhibitorem isozymu 3A4 cytochromu P450 a/nebo inhibitorem P-glykoproteinu
AU2002363523A1 (en) * 2001-11-07 2003-05-19 Pharmacia Corporation Methods of promoting uptake and nuclear accumulation of polyamides in eukaryotic cells
US7714006B1 (en) 2001-12-03 2010-05-11 King Pharmaceuticals Research & Development, Inc. Methods of modifying the bioavailability of metaxalone
US6407128B1 (en) 2001-12-03 2002-06-18 Elan Pharmaceuticals, Inc. Method for increasing the bioavailability of metaxalone
WO2003055494A1 (en) * 2001-12-21 2003-07-10 Avmax, Inc. Use of ugt inhibitors to increase bioavailability
US7169763B2 (en) * 2002-02-22 2007-01-30 Oliver Yoa-Pu Hu Cytochrome P450 3A inhibitors and enhancers
WO2003104439A2 (en) * 2002-03-12 2003-12-18 Surface Logix, Inc. Assay device that analyzes the absorption, metabolism, permeability and/or toxicity of a candidate compound
WO2004037161A2 (en) 2002-05-13 2004-05-06 Metabasis Therapeutics, Inc. Cyclic prodrugs of pmea one of its analogues
NZ536327A (en) * 2002-05-13 2007-08-31 Metabasis Therapeutics Inc PMEA and PMPA cyclic producing synthesis
US6905839B2 (en) * 2002-07-31 2005-06-14 Takashi Furuta In vivo phenotyping for human cytochrome P450 3A activity
ATE411010T1 (de) * 2002-12-13 2008-10-15 Jagotec Ag Topische nanopartikel-spironolacton-formulierung
JP2006514662A (ja) * 2003-02-12 2006-05-11 アンスティテュ、ナショナル、ド、ラ、サント、エ、ド、ラ、ルシェルシュ、メディカル（アンセルム） コロイド状キャリヤーの表面におけるｐ糖タンパク質インヒビター界面活性剤の使用
AU2004212989A1 (en) * 2003-02-20 2004-09-02 Teva Pharmaceutical Industries Ltd. Menthol solutions of drugs
JP2004359665A (ja) * 2003-05-30 2004-12-24 Rohm & Haas Co 生体利用性増強剤を含有する治療組成物
WO2004109279A2 (en) * 2003-06-09 2004-12-16 Pfizer Products Inc. Sensitive and selective in vitro assay for the detection of reactive drug intermediates
US20050131028A1 (en) * 2003-09-11 2005-06-16 Pharmacia Corporation Methods and compositions for the extended duration treatment of pain, inflammation and inflammation-related disorders
WO2005117697A2 (en) * 2004-05-28 2005-12-15 Narayanan Ramasubramanian Unified indigestion package and process for patient compliance with prescribed medication regimen
CN1964967B (zh) * 2004-06-08 2014-04-16 症变治疗公司 路易斯酸介导的环状酯的合成
US7244765B2 (en) * 2004-06-25 2007-07-17 Cytokine Pharmasciences, Inc Guanylhydrazone salts, compositions, processes of making and methods of using
AR050043A1 (es) 2004-08-03 2006-09-20 Novartis Ag Metodos para mejorar la biodisponibilidad y composicion farmaceutica para trastornos cardiovasculares
CN101010114B (zh) 2004-08-27 2010-05-26 皇家飞利浦电子股份有限公司 电子遥控药丸和用于供应至少一种药物的系统
BRPI0518322A2 (pt) * 2004-11-16 2008-11-18 Limerick Neurosciences Inc composiÇço, kit, e, mÉtodos para tratar uma condiÇço, para reverter um efeito no sistema nervoso central de um agente, para tratar um animal de dor, e para controlar dor crânica
US20070087977A1 (en) * 2004-11-16 2007-04-19 Wendye Robbins Methods and compositions for treating pain
US20090234331A1 (en) * 2004-11-29 2009-09-17 Koninklijke Philips Electronics, N.V. Electronically controlled pill and system having at least one sensor for delivering at least one medicament
US20060222627A1 (en) * 2005-03-30 2006-10-05 Andrew Carter Optimizing pharmacodynamics of therapeutic agents for treating vascular tissue
WO2006110656A2 (en) * 2005-04-08 2006-10-19 Chimerix, Inc. Compounds, compositions and methods for the treatment of viral infections and other medical disorders
US20070190188A1 (en) * 2005-12-13 2007-08-16 The University Of Mississippi Controlling Toxicity of Aminoquinoline Compounds
EP3696171A1 (de) * 2006-07-07 2020-08-19 Gilead Sciences, Inc. Modulatoren der pharmakokinetischen eigenschaften von therapeutika
US8217025B2 (en) * 2006-11-17 2012-07-10 Harbor Therapeutics, Inc. Drug screening and treatment methods
EP3150586B1 (de) 2007-02-23 2020-01-08 Gilead Sciences, Inc. Modulatoren der pharmakokinetischen eigenschaften von therapeutika
US20080207745A1 (en) * 2007-02-24 2008-08-28 Sri International Orally-absorbed formulation for paromomycin
US8622991B2 (en) 2007-03-19 2014-01-07 Insuline Medical Ltd. Method and device for drug delivery
WO2008114220A2 (en) * 2007-03-19 2008-09-25 Insuline Medical Ltd. Device for drug delivery and associated connections thereto
CN104069567A (zh) 2007-03-19 2014-10-01 茵苏莱恩医药有限公司 药物输送设备
US9220837B2 (en) 2007-03-19 2015-12-29 Insuline Medical Ltd. Method and device for drug delivery
US20090088393A1 (en) * 2007-09-28 2009-04-02 Zomanex, Llc Methods and formulations for converting intravenous and injectable drugs into oral dosage forms
US20090111736A1 (en) * 2007-10-29 2009-04-30 Sri International Orally-Absorbed Solid Dose Formulation for Vancomycin
EP2231229A1 (de) 2007-12-18 2010-09-29 Insuline Medical Ltd. Wirkstofffreisetzungsvorrichtung mit sensor für geschlossenen kreislauf
WO2009094190A2 (en) 2008-01-25 2009-07-30 Chimerix, Inc. Methods of treating viral infections
US20100331827A1 (en) * 2008-02-18 2010-12-30 Koninklijke Philips Electronics N.V. Administration of drugs to a patient
CN101983029B (zh) * 2008-03-31 2015-01-14 皇家飞利浦电子股份有限公司 制备包括传感器的可吞服胶囊的方法
JP5627569B2 (ja) 2008-04-30 2014-11-19 シーメンス メディカル ソリューションズ ユーエスエー インコーポレイテッドＳｉｅｍｅｎｓ Ｍｅｄｉｃａｌ Ｓｏｌｕｔｉｏｎｓ ＵＳＡ，Ｉｎｃ． 新規基質に基づくｐｅｔ造影剤
EP2303361B1 (de) * 2008-06-19 2015-02-25 Medimetrics Personalized Drug Delivery B.V. Kapsel zur abgabe von pulverförmigem medikament in den verdauungstrakt
RU2011102576A (ru) * 2008-06-25 2012-07-27 Конинклейке Филипс Электроникс Н.В. (Nl) Электронная таблетка, содержащая множество емкостей с лекарственным средствами
US7916989B2 (en) * 2008-07-31 2011-03-29 Corning Cable Systems Llc Optical fiber assemblies having a powder or powder blend at least partially mechanically attached
US20110312985A1 (en) * 2008-10-08 2011-12-22 The General Hospital Corporation Naringenin complexes and methods of use thereof
EP2355758A2 (de) 2008-11-07 2011-08-17 Insuline Medical Ltd. Arzneimittelabgabevorrichtung und -verfahren
JP5497176B2 (ja) 2009-08-12 2014-05-21 コーニンクレッカ フィリップス エヌ ヴェ 圧縮可能な薬品貯槽を備える薬品送出装置
US9717703B2 (en) 2009-10-16 2017-08-01 Glaxosmithkline Llc Emulsion and emulsion preconcentrate compositions comprising omega-3 fatty acids and uses thereof are disclosed
HUE032860T2 (en) 2010-02-12 2017-11-28 Chimerix Inc A method for treating a virus infection
WO2011139709A2 (en) 2010-04-26 2011-11-10 Chimerix, Inc. Methods of treating retroviral infections and related dosage regimes
JP2011231127A (ja) * 2011-08-01 2011-11-17 Sekisui Medical Co Ltd 経口吸収改善剤およびこれを利用する医薬組成物
US9078925B2 (en) 2012-06-18 2015-07-14 Galephar Pharmaceutical Research, Inc. Pharmaceutical semi-solid composition of isotretinoin
KR102186116B1 (ko) 2012-11-20 2020-12-03 스펙트럼 파마슈티컬즈 인크 치료적 사용을 위한 리포솜 캡슐화 빈크리스틴을 제조하기 위한 개선된 방법
WO2015123352A1 (en) 2014-02-13 2015-08-20 Ligand Pharmaceuticals, Inc. Prodrug compounds and their uses
WO2015179074A1 (en) * 2014-05-19 2015-11-26 Health Science Funding Llc Improved antibacterial therapy
JP2017520545A (ja) 2014-07-02 2017-07-27 リガンド・ファーマシューティカルズ・インコーポレイテッド プロドラッグ化合物およびそれらの使用
PT3223796T (pt) * 2014-11-25 2021-09-28 Curadigm Sas Composições farmacêuticas, preparação e suas utilizações
CN104606677B (zh) * 2014-12-15 2018-04-03 中山大学 一种提高紫杉醇口服生物利用度的紫杉烷类组合物及其应用
TWI678213B (zh) 2015-07-22 2019-12-01 美商史倍壯製藥公司 用於長春新鹼硫酸鹽脂質體注射之即可使用的調配物
US11617715B2 (en) * 2016-08-02 2023-04-04 Texas Tech University System Methods and compositions for modifying the behavior of animals

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH550586A (de) * 1971-04-08 1974-06-28 Espe Pharm Praep Spuel- und reinigungsmittel fuer schleimhaeute.
EP0127677B1 (de) * 1982-12-09 1990-08-01 Advanced Drug Technology, Inc. Einfach absorbierbare fettsäureemulsionen
US4693966A (en) * 1983-03-11 1987-09-15 Sloan-Kettering Institute For Cancer Research Human monoclonal antibodies from lymphocytes of patients with malignant melanoma
US5231112A (en) * 1984-04-12 1993-07-27 The Liposome Company, Inc. Compositions containing tris salt of cholesterol hemisuccinate and antifungal
US5639724A (en) * 1984-07-24 1997-06-17 Sandoz Ltd. Cyclosporin galenic forms
US4849227A (en) * 1986-03-21 1989-07-18 Eurasiam Laboratories, Inc. Pharmaceutical compositions
GB8630273D0 (en) * 1986-12-18 1987-01-28 Til Medical Ltd Pharmaceutical delivery systems
US4751220A (en) * 1986-12-19 1988-06-14 E. R. Squibb & Sons, Inc. Crystalline salts of [3S(Z)]-2[[[1-(2-amino-4-thiazolyl)-2-[[2,2-dimethyl-4-oxo-1-(sulfooxy)-3-azetidinyl]amino]-2-oxoethylidene]-amino]oxy]acetic acid
US5070085A (en) * 1987-04-10 1991-12-03 Oxycal Laboratories, Inc. Compositions and methods for administering therapeutically active compounds
US4822816A (en) * 1987-04-10 1989-04-18 Oxycal Laboratories, Inc. Compositions and methods for administering vitamin C
US4968716A (en) * 1987-04-10 1990-11-06 Oxycal Laboratories, Inc. Compositions and methods for administering therapeutically active compounds
IE59934B1 (en) * 1987-06-19 1994-05-04 Elan Corp Plc Liquid suspension for oral administration
GB8909022D0 (en) * 1989-04-20 1989-06-07 Cortecs Ltd Pharmaceutical compositions
GB8914040D0 (en) * 1989-06-19 1989-08-09 Wellcome Found Agents for potentiating the effects of antitumour agents and combating multiple drug resistance
US5411947A (en) * 1989-06-28 1995-05-02 Vestar, Inc. Method of converting a drug to an orally available form by covalently bonding a lipid to the drug
EP0487575B1 (de) * 1989-08-17 1994-11-02 Cortecs Limited Arzneiformulierungen
US5332747A (en) * 1989-09-28 1994-07-26 Cancer Biologics Of America, Inc. Method for potentiating primary drugs in treating multidrug resistant parasitic disease cells
GB9022788D0 (en) * 1990-10-19 1990-12-05 Cortecs Ltd Pharmaceutical formulations
US5179122A (en) * 1991-02-11 1993-01-12 Eastman Kodak Company Nutritional supplement containing vitamin e
US5350756A (en) * 1991-06-17 1994-09-27 Smith Richard A Use of a cytochrome oxidase inhibitor to increase the cough-suppressing activity of dextromorphan
US5366980A (en) * 1991-06-17 1994-11-22 Smith Richard A Use of dextromethorphan and an oxidase inhibitor to treat dermatitis
US5221698A (en) * 1991-06-27 1993-06-22 The Regents Of The University Of Michigan Bioactive composition
ES2153362T3 (es) * 1991-08-26 2001-03-01 Abbott Lab Composiciones y procedimientos de administracion sublingual o bucal de agentes terapeuticos.
WO1993024476A1 (en) * 1992-06-04 1993-12-09 Clover Consolidated, Limited Water-soluble polymeric carriers for drug delivery
US5466696A (en) * 1992-09-10 1995-11-14 Warner Lambert Company Tacrine and cytochrome P450 oxidase inhibitors and methods of use
US5422350A (en) * 1992-09-10 1995-06-06 Warner-Lambert Company Nitrogen substituted acridine and cytochrome P450 inhibitors and methods of use
US5643909A (en) * 1993-04-19 1997-07-01 Syntex (U.S.A.) Inc. 10,11-Methanodibenzosuberane derivatives
US5359030A (en) * 1993-05-10 1994-10-25 Protein Delivery, Inc. Conjugation-stabilized polypeptide compositions, therapeutic delivery and diagnostic formulations comprising same, and method of making and using the same
FR2706771A1 (en) * 1993-06-21 1994-12-30 Pelletier Jacques Formula for the treatment of certain cancers.
US5409690A (en) * 1993-06-23 1995-04-25 Chemex Pharmaceuticals, Inc. Treatment of multidrug resistant diseases in cancer cell by potentiating with masoprocol
JP4850985B2 (ja) * 1993-07-29 2012-01-11 アメリカ合衆国 微小管安定化剤を用いたアテローム性動脈硬化症または再狭窄症の治療方法
US5424289A (en) * 1993-07-30 1995-06-13 Alza Corporation Solid formulations of therapeutic proteins for gastrointestinal delivery
US5436243A (en) * 1993-11-17 1995-07-25 Research Triangle Institute Duke University Aminoanthraquinone derivatives to combat multidrug resistance
US5567592A (en) * 1994-02-02 1996-10-22 Regents Of The University Of California Screening method for the identification of bioenhancers through the inhibition of P-glycoprotein transport in the gut of a mammal

Also Published As

Publication number Publication date
EP0742722B1 (de) 2002-04-17
US5567592A (en) 1996-10-22
US6004927A (en) 1999-12-21
JP2006045244A (ja) 2006-02-16
EP0742722A1 (de) 1996-11-20
US6028054A (en) 2000-02-22
JPH09508623A (ja) 1997-09-02
DE69526428T2 (de) 2002-10-10
ATE216260T1 (de) 2002-05-15
AU1562995A (en) 1995-08-21
EP1127579A3 (de) 2004-01-21
ES2174928T3 (es) 2002-11-16
WO1995020980A1 (en) 1995-08-10
EP1127579A2 (de) 2001-08-29
CA2177175A1 (en) 1995-08-10
DK0742722T3 (da) 2002-06-17

Similar Documents

Publication Publication Date Title
DE69526428T2 (de) Verfahren zur erhöhung der bioverfügbarkeit oraler arzneimittel
BG104620A (en) Oral pharmaceutical extended release dosage form
CA2301017A1 (en) Use of propyl gallate to increase bioavailability of orally administered pharmaceutical compounds
LU90943I2 (fr) Kineret-anakinra et ses dérivés pharmaceutiquement acceptables
CO4940450A1 (es) Formulaciones farmaceuticas que contienen voriconazol
DE69534264D1 (de) Facettenreiches verfahren zur unterdrückung der vermehrung latenter viren in menschen und tieren
NO944803L (no) Farmasöytisk preparat for kontrollert frigivelse
SE0001330D0 (sv) Novel method of treatment
EP0773022A3 (de) Pharmazeutische Zubereitung zur Behandlung akuter Rhinitiden, enthaltend Sympthomimeticum und Pantothenol und/oder Pantothensäure
DE60045114D1 (de) Zubereitungen zur Erhöhung der Bioverfügbarkeit von oral verabreichten pharmazeutischen Verbindungen
AU3003189A (en) 7(2-(2-aminothiazol-4-yl)-2-hydroxyimino-acetamido)-3- methoxymethyl-3-cephem-4-carboxylate ester derivatives
GB9907571D0 (en) Compounds
NO178336C (no) Analogifremgangsmåte for fremstilling av en terapeutisk aktiv benzimidazolforbindelse og mellomprodukter
GR3025951T3 (en) Alpha amino acid derivatives, a method for their preparation and pharmaceutical preparations containing them.
FI945510A (fi) Klavulaanihapon diamiinisuolat
EA199901116A1 (ru) Композиция, включающая 5-[4-[2-(n-метил-n-2-пиридил)-амино)этокси]бензил]тиазолидин-2,4-дион
AR002191A1 (es) Composicion farmaceutica oral de compuestos de piperidinoalcanol en forma de solucion, procedimiento para su preparacion
DE58907678D1 (de) 6-Fluor-3,5-dihydroxycarbonsäuren und deren Derivate, Verfahren zu ihrer Herstellung, ihre Verwendung als Arzneimittel, pharmazeutische Präparate und Zwischenprodukte.
ES2117114T3 (es) Nuevos derivados de tiaxolidin-diona, su procedimiento de preparacion y composiciones farmaceuticas que los contienen.
AU1509388A (en) Substituted quinoxalyl-imidazolidine-2,4-diones, processes for their preparation, their use as medicaments and pharmaceutical preparations
CY1107421T1 (el) Τρυγικα αλατα παραγωγου θειαζολιδινοδιονης
DE69208913D1 (de) 2-Oxindol-1-carboxamidderivat enthaltendes Arzneimittel zur rektalen Verabreichung
MX9601033A (es) Nanosuspensiones para administracion intravenosa.
JO2040B1 (en) Method for preparing salts and esters (bacilli salts) from clavulic acid
AU7586191A (en) Hydroxyproline derivative, a process for the preparation thereof and pharmaceutical compositions containing it

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee